APVO
Aptevo Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.74
+1.75%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | 3.1M |
| Cost of Revenue | 116.0K | 240.0K | 352.0K | — | — |
| Gross Profit | (116.0K) | (240.0K) | (352.0K) | — | 3.1M |
| Operating Expenses | |||||
| R&D Expense | 15.2M | 14.5M | 14.4M | 17.1M | 17.9M |
| SG&A Expense | 11.7M | 11.8M | 10.2M | 11.8M | 13.9M |
| General & Admin Expense | 11.7M | 11.8M | 10.2M | 11.8M | 13.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (81.0K) | (240.0K) | (352.0K) | — | — |
| Total Operating Expenses | 26.8M | 26.1M | 24.3M | 28.9M | 31.8M |
| Cost and Expenses | 26.9M | 26.3M | 24.6M | 28.9M | 31.8M |
| Operating Income (EBIT) | (26.9M) | (26.3M) | (24.6M) | (28.9M) | (28.6M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | 478.0K | 345.0K | 472.0K | 10.2M | 35.7M |
| Non-Operating Income (excl Interest) | (304.0K) | (345.0K) | (472.0K) | (10.2M) | (35.7M) |
| EBT (Pre-Tax Income) | (26.4M) | (26.0M) | (24.1M) | (18.6M) | 7.0M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (26.4M) | (26.0M) | (24.1M) | (17.4M) | 8.0M |
| Earnings from Cont. Ops | (26.4M) | (26.0M) | (24.1M) | (18.6M) | 7.0M |
| Earnings from Discont. Ops | — | — | — | 1.2M | 1.0M |
| Bottom Line Net Income | (28.1M) | (27.5M) | (24.1M) | (17.4M) | 8.0M |
| Per Share | |||||
| Basic EPS | ($211.18) | ($87.27) | ($31,458.00) | ($834,044.00) | $922,390.00 |
| Diluted EPS | ($211.18) | ($87.27) | ($31,458.00) | ($834,044.00) | $921,915.00 |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $357,831.91 |
| Shares | |||||
| Basic Shares Outstanding | 1.2M | 3155 | 767 | 21 | 9 |
| Diluted Shares Outstanding | 1.2M | 3155 | 767 | 21 | 9 |
| Profitability Metrics | |||||
| EBITDA | (26.4M) | (25.7M) | (23.8M) | (18.1M) | 7.9M |
| D&A | 165.0K | 240.0K | 352.0K | 567.0K | 901.0K |
| EBIT | (26.6M) | (26.0M) | (24.1M) | (18.6M) | 7.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026